Related Experiment Videos
Neuroprotective interactions in rats between paclitaxel and cisplatin
M J McKeage1, G G Haddad, L Ding
1Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand. m.mckeage@auckland.ac.nz
Oncology Research
|February 26, 2000
Summary
Combining paclitaxel and cisplatin with paclitaxel first antagonized their neurotoxicity in rats, reducing nerve damage. This combination also enhanced antitumor activity, suggesting a strategy to minimize chemotherapy side effects.
Area of Science:
- Pharmacology
- Neuroscience
- Oncology
Background:
- Paclitaxel and cisplatin cause dose-limiting neurotoxicity due to differing effects on microtubule stability.
- This neurotoxicity impacts peripheral nerves, potentially limiting chemotherapy efficacy.
- Exploiting these differing mechanisms could mitigate adverse effects.
Purpose of the Study:
- To investigate if combining paclitaxel and cisplatin, administered 24 hours apart, could minimize their neurotoxicity.
- To evaluate the impact of this combination on neurotoxicity and antitumor activity.
- To determine the optimal sequence for minimizing neurotoxicity.
Main Methods:
- Female Wistar rats received paclitaxel and cisplatin alone or in combination (24 hours apart) weekly for 7-10 weeks.
- Sensory nerve conduction velocity (SNCV) and dorsal root ganglia (DRG) morphology were assessed.
- Antitumor activity was evaluated in C57B1/6 mice bearing colon 38 tumors.
Main Results:
- Paclitaxel administered 24 hours before cisplatin significantly reduced neurotoxicity (no change in SNCV) compared to other combinations.
- The combination of paclitaxel followed by cisplatin showed less-than-additive or antagonistic neurotoxic effects.
- This sequence also enhanced antitumor activity (7.5 days tumor growth delay) compared to single agents.
Conclusions:
- Paclitaxel and cisplatin exhibit an antagonistic interaction regarding neurotoxicity when administered in a specific sequence.
- Administering paclitaxel 24 hours before cisplatin minimizes neurotoxicity while enhancing antitumor effects.
- This sequential combination strategy holds promise for reducing chemotherapy-induced peripheral neuropathy in patients.